Intuitive Surgical, Inc. (NASDAQ:ISRG) Receives Consensus Rating of “Moderate Buy” from Brokerages

Intuitive Surgical, Inc. (NASDAQ:ISRG) has been given an average rating of “Moderate Buy” by the seventeen analysts that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $396.17.

Several research analysts have recently issued reports on the stock. Piper Sandler raised their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Truist Financial lifted their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Mizuho lifted their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Raymond James lifted their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th.

Intuitive Surgical Trading Up 0.6 %

Shares of NASDAQ ISRG opened at $375.33 on Friday. The firm has a market capitalization of $133.13 billion, a PE ratio of 67.75, a price-to-earnings-growth ratio of 4.84 and a beta of 1.36. Intuitive Surgical has a 1 year low of $254.85 and a 1 year high of $403.76. The firm’s 50-day moving average is $386.19 and its 200-day moving average is $345.95.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.00 EPS. As a group, equities research analysts anticipate that Intuitive Surgical will post 4.8 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at $2,168,656.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders have sold 249,418 shares of company stock worth $96,300,959 over the last ninety days. Insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently added to or reduced their stakes in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of Intuitive Surgical by 0.3% in the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after buying an additional 27 shares during the period. Advance Capital Management Inc. increased its position in Intuitive Surgical by 3.8% during the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 27 shares during the period. Sheaff Brock Investment Advisors LLC increased its position in Intuitive Surgical by 1.3% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 29 shares during the period. Sugarloaf Wealth Management LLC increased its position in Intuitive Surgical by 5.7% during the 1st quarter. Sugarloaf Wealth Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 29 shares during the period. Finally, Liberty Capital Management Inc. increased its position in Intuitive Surgical by 3.8% during the 4th quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 30 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.